GSK Plc: New Data Shows Vaccine Efficacy Of Arexvy Against RSV-lower Respiratory Tract Disease
21/6 08:29
(RTTNews) - GSK plc (GSK, GSK.L) reported new data from the AReSVi-006 phase III trial evaluating the efficacy of a single dose of Arexvy, the company's respiratory syncytial virus older adult vaccine, against lower respiratory tract disease in adults aged 60 years and older. The...